XML 46 R33.htm IDEA: XBRL DOCUMENT v3.23.2
REVENUES (Tables)
 6 Months Ended
Jun. 30, 2023
Revenue from Contract with Customer [Abstract]  
Contract with Customer, Contract Asset The following table summarizes our contract assets:
(in millions)June 30,
2023		December 31,
2022
Contract manufacturing services$4 $10 
Software sales43 43 
Bundled equipment and consumable medical products contracts116 121 
Contract assets$163 $174 
The following table summarizes contract liability activity for the six months ended June 30, 2023 and 2022. The contract liability balance represents the transaction price allocated to the remaining performance obligations.
Six Months Ended June 30,
(in millions)
2023
2022
Balance at beginning of period$194 $196 
New revenue deferrals271 282 
Revenue recognized upon satisfaction of performance obligations(267)(289)
Currency translation1 (5)
Balance at end of period$199 $184 
For the six months ended June 30, 2023 and 2022, $64 million and $77 million of revenue was recognized that was included in contract liabilities as of December 31, 2022 and 2021, respectively.
The following table summarizes the classification of contract assets and contract liabilities as reported in the condensed consolidated balance sheets:
(in millions)June 30,
2023		December 31,
2022
Prepaid expenses and other current assets$49 $52 
Other non-current assets114 122 
Contract assets$163 $174 
Accrued expenses and other current liabilities$158 $154 
Other non-current liabilities41 40 
Contract liabilities$199 $194 
Net Sales from Contracts with Customers by Global Business Unit The following tables disaggregate our net sales from contracts with customers by product category between the U.S. and international:
Three Months Ended June 30,
20232022
(in millions)U.S.InternationalTotalU.S.InternationalTotal
Renal Care 1
$234 $702 $936 $225 $706 $931 
Medication Delivery 2
487 274 761 459 251 710 
Pharmaceuticals 3
182 368 550 164 364 528 
Clinical Nutrition 4
83 160 243 90 140 230 
Advanced Surgery 5
150 122 272 151 112 263 
Acute Therapies 6
60 120 180 58 115 173 
Patient Support Systems 7
276 83 359 284 80 364 
Front Line Care 8
227 80 307 202 80 282 
Global Surgical Solutions 9
35 42 77 36 33 69 
Other 10
17 5 22 31 13 44 
Total Baxter$1,751 $1,956 $3,707 $1,700 $1,894 $3,594 
Six Months Ended June 30,
20232022
(in millions)U.S.InternationalTotalU.S.InternationalTotal
Renal Care 1
$466 $1,362 $1,828 $450 $1,375 $1,825 
Medication Delivery 2
923 525 1,448 931 485 1,416 
Pharmaceuticals 3
355 719 1,074 321 728 1,049 
Clinical Nutrition 4
161 306 467 174 283 457 
Advanced Surgery 5
294 224 518 287 204 491 
Acute Therapies 6
121 239 360 126 235 361 
Patient Support Systems 7
536 171 707 579 168 747 
Front Line Care 8
448 161 609 409 167 576 
Global Surgical Solutions 9
73 85 158 73 74 147 
Other 10
41 10 51 62 21 83 
Total Baxter$3,418 $3,802 $7,220 $3,412 $3,740 $7,152 
1Renal Care includes sales of our peritoneal dialysis (PD), HD and additional dialysis therapies and services.
2Medication Delivery includes sales of our intravenous (IV) therapies, infusion pumps, administration sets and drug reconstitution devices.
3Pharmaceuticals includes sales of our premixed and oncology drug platforms, inhaled anesthesia and critical care products and pharmacy compounding services.
4Clinical Nutrition includes sales of our parenteral nutrition therapies and related products.
5Advanced Surgery includes sales of our biological products and medical devices used in surgical procedures for hemostasis, tissue sealing and adhesion prevention.
6Acute Therapies includes sales of our continuous renal replacement therapies (CRRT) and other organ support therapies focused in the intensive care unit (ICU).
7Patient Support Systems includes sales of our connected care solutions: devices, software, communications and integration technologies and smart beds.
8Front Line Care includes sales of our integrated patient monitoring and diagnostic technologies to help diagnose, treat and manage a wide variety of illness and diseases, including respiratory therapy, cardiology, vision screening and physical assessment.
9Global Surgical Solutions includes sales of our surgical video technologies, tables, lights, pendants, precision positioning devices and other accessories.
10Other includes sales of miscellaneous product and service offerings. Contract manufacturing revenues earned by our manufacturing facility in Round Lake Illinois, which totaled $2 million for the six months ended June 30, 2023 and $11 million and $18 million for the three and six months ended June 30, 2022, respectively, were historically presented as BPS sales. Those sales transactions, which are not impacted by the pending divestiture of our BPS business, continue to be presented as continuing operations in the accompanying consolidated financial statements and have been reclassified to our Other product category for all periods presented.
Sales-type Lease, Lease Income
The components of lease revenue for the three and six months ended June 30, 2023 and 2022 were:
(in millions)Three months ended June 30, 2023Six Months Ended June 30, 2023
Sales-type lease revenue$3 $7 
Operating lease revenue132 256 
Variable lease revenue14 29 
Total lease revenue$149 $292 
(in millions)Three months ended June 30, 2022Six months ended June 30, 2022
Sales-type lease revenue$5 $8 
Operating lease revenue113 235 
Variable lease revenue12 32 
Total lease revenue$130 $275 
Operating Lease, Lease Income
The components of lease revenue for the three and six months ended June 30, 2023 and 2022 were:
(in millions)Three months ended June 30, 2023Six Months Ended June 30, 2023
Sales-type lease revenue$3 $7 
Operating lease revenue132 256 
Variable lease revenue14 29 
Total lease revenue$149 $292 
(in millions)Three months ended June 30, 2022Six months ended June 30, 2022
Sales-type lease revenue$5 $8 
Operating lease revenue113 235 
Variable lease revenue12 32 
Total lease revenue$130 $275